Security
Taysha Gene Therapies, Inc. Common Stock · TSHA
TSHANASDAQCommon stockCurrentCIK 1806310Updated Oct 6, 2026
TSHA price & chart
Loading TradingView…
NASDAQ:TSHA on TradingView ↗About the company
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit www.tayshagtx.com.
In the news
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ↗
Recent filings
SCHEDULE 13G/A - filed by RA CAPITAL MANAGEMENT, L.P. regarding Taysha Gene Therapies, Inc.
SCHEDULE 13G/A - filed by MORGAN STANLEY regarding Taysha Gene Therapies, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Show 5 more recent filings
144 filing
Entry into a Material Definitive Agreement · Other Events
Items 1.01, 8.01, 9.01
424B5 filing
424B5 filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 316,554,000Source | 180,217,000Source | 470,433,000Source | 333,331,000Source | 200,393,000Source | 300,351,000Source | 138,362,000Source | 152,999,000Source | 343,320,000Source | 160,364,000Source | 172,731,000Source | 126,276,000Source |
| Property, Plant and Equipment, NetUSD | 6,805,000Source | 7,613,000Source | 2,412,000Source | 6,957,000Source | 10,513,000Source | 6,450,000Source | 7,236,000Source | 10,686,000Source | 6,736,000Source | 7,485,000Source | 10,826,000Source | 14,963,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 297,344,000Source | 157,688,000Source | 455,407,000Source | 312,761,000Source | 172,743,000Source | 276,576,000Source | 116,593,000Source | 123,980,000Source | 319,767,000Source | 139,036,000Source | 143,940,000Source | 87,880,000Source |
| Assets, CurrentUSD | 299,951,000Source | 161,555,000Source | 461,434,000Source | 316,264,000Source | 178,470,000Source | 282,250,000Source | 120,708,000Source | 130,597,000Source | 324,647,000Source | 142,130,000Source | 149,868,000Source | 96,417,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,158,000Source | 3,418,000Source | 6,027,000Source | 3,054,000Source | 3,278,000Source | 5,225,000Source | 3,666,000Source | 4,168,000Source | 4,431,000Source | 2,645,000Source | 3,479,000Source | 8,537,000Source |
| Operating Lease, Right-of-Use AssetUSD | 7,463,000Source | 8,678,000Source | 6,317,000Source | 7,773,000Source | 8,971,000Source | 9,155,000Source | 8,079,000Source | 9,261,000Source | 9,439,000Source | 8,381,000Source | 9,582,000Source | 10,943,000Source |
| Other Assets, NoncurrentUSD | 184,000Source | 220,000Source | 106,000Source | 186,000Source | 288,000Source | 181,000Source | 188,000Source | 304,000Source | 183,000Source | 217,000Source | 304,000Source | 1,316,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 97,565,000Source | 91,420,000Source | 83,167,000Source | 84,604,000Source | 91,525,000Source | 88,407,000Source | 83,303,000Source | 99,150,000Source | 96,382,000Source | 88,839,000Source | 97,794,000Source | 125,327,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,000Source | 2,000Source | 3,000Source | 3,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 3,000Source | 2,000Source | 2,000Source | 1,000Source |
| Additional Paid in CapitalUSD | 903,578,000Source | 674,643,000Source | 1,186,843,000Source | 900,139,000Source | 664,457,000Source | 964,666,000Source | 681,177,000Source | 591,166,000Source | 958,427,000Source | 677,859,000Source | 587,942,000Source | 402,389,000Source |
| Retained Earnings (Accumulated Deficit)USD | -683,449,000Source | -583,520,000Source | -800,349,000Source | -650,716,000Source | -557,996,000Source | -753,710,000Source | -623,834,000Source | -537,068,000Source | -711,300,000Source | -602,305,000Source | -513,007,000Source | -401,441,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -1,143,000Source | -2,328,000Source | 769,000Source | -699,000Source | 2,405,000Source | 985,000Source | -2,286,000Source | -251,000Source | -192,000Source | -4,031,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | 218,989,000Source | 88,797,000Source | 387,266,000Source | 248,727,000Source | 108,868,000Source | 211,944,000Source | 55,059,000Source | 53,849,000Source | 246,938,000Source | 71,525,000Source | 74,937,000Source | 949,000Source |
| Liabilities and EquityUSD | 316,554,000Source | 180,217,000Source | 470,433,000Source | 333,331,000Source | 200,393,000Source | 300,351,000Source | 138,362,000Source | 152,999,000Source | 343,320,000Source | 160,364,000Source | 172,731,000Source | 126,276,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 28,631,000Source | 29,335,000Source | 25,975,000Source | 25,349,000Source | 34,176,000Source | 20,098,000Source | 22,557,000Source | 38,637,000Source | 26,552,000Source | 26,227,000Source | 36,756,000Source | 62,790,000Source |
| Operating Lease, Liability, CurrentUSD | 1,245,000Source | 1,434,000Source | 996,000Source | 1,326,000Source | 1,383,000Source | 1,549,000Source | 1,406,000Source | 1,334,000Source | 1,486,000Source | 1,486,000Source | 1,292,000Source | 1,201,000Source |
| Accounts Payable, CurrentUSD | 5,438,000Source | 4,932,000Source | 9,164,000Source | 7,713,000Source | 8,718,000Source | 4,564,000Source | 4,326,000Source | 10,380,000Source | 6,275,000Source | 3,592,000Source | 6,366,000Source | 10,946,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,506,000Source | 17,751,000Source | 6,291,000Source | 16,808,000Source | 18,134,000Source | 17,766,000Source | 17,093,000Source | 18,499,000Source | 18,172,000Source | 17,361,000Source | 18,953,000Source | 20,440,000Source |
| Other Liabilities, NoncurrentUSD | 1,576,000Source | 1,363,000Source | 1,641,000Source | 1,396,000Source | 1,380,000Source | 1,582,000Source | 1,200,000Source | 1,502,000Source | 1,552,000Source | 1,309,000Source | 1,577,000Source | 4,130,000Source |
| Additional Financial Items | ||||||||||||
| Deferred Revenue, CurrentUSD | 5,485,000Source | 11,795,000Source | — | 5,485,000Source | 13,583,000Source | — | 7,470,000Source | 14,695,000Source | — | 9,773,000Source | 18,106,000Source | 33,557,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | 2,682,000Source | 1,912,000Source | 2,226,000Source | 2,355,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 50,852,000Source | 42,971,000Source | 49,260,000Source | 41,051,000Source | 37,835,000Source | 48,961,000Source | 42,453,000Source | 40,512,000Source | 50,106,000Source | 43,942,000Source | 40,508,000Source | 37,967,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | -32,733,000Source | -25,524,000Source | -46,639,000Source | -26,882,000Source | -42,410,000Source | -21,529,000Source | -108,995,000Source | -89,298,000Source | -111,566,000Source | -166,014,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 5,547,000Source | 3,294,000Source | 13,298,000Source | 13,103,000Source | 7,905,000Source | 18,043,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 1,289,000Source | 923,000Source | -153,000Source | -2,920,000Source | -2,295,000Source | -7,804,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -40,878,000Source | -22,020,000Source | -93,090,000Source | -81,225,000Source | -73,018,000Source | -88,390,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -3,024,000Source | -371,000Source | -604,000Source | -363,000Source | -7,352,000Source | -24,930,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | — | -7,000Source | -134,000Source | -11,000Source | -17,000Source | 61,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 24,000Source | 378,000Source | 738,000Source | 374,000Source | 3,869,000Source | 20,619,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 711,000Source | -52,000Source | 274,589,000Source | 76,684,000Source | 136,393,000Source | 52,097,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | 19,000Source | -80,000Source | -337,000Source | -167,000Source | -229,000Source | -1,042,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -43,191,000Source | -22,443,000Source | 180,895,000Source | -4,904,000Source | 56,023,000Source | -61,223,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 1,447,000Source | 1,294,000Source | 5,399,000Source | 5,282,000Source | 4,952,000Source | 2,775,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 3,285,000Source | 3,357,000Source | 5,810,000Source | 3,190,000Source | 5,547,000Source | 3,294,000Source | 13,298,000Source | 13,103,000Source | 7,905,000Source | 18,043,000Source |
| DepreciationUSD | — | — | 200,000Source | 300,000Source | 400,000Source | 300,000Source | 295,000Source | 283,000Source | 1,145,000Source | 1,245,000Source | 1,371,000Source | 1,172,000Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | 100,000Source | — | — | 100,000Source | — | — | — |
| Gain (Loss) on Sale of Assets and Asset Impairment ChargesUSD | — | — | — | — | — | — | — | — | — | -4,800,000Source | -600,000Source | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | -1,398,000Source | — |
| General and Administrative ExpenseUSD | — | — | 8,279,000Source | 7,902,000Source | 12,146,000Source | 8,598,000Source | 9,677,000Source | 8,158,000Source | 33,868,000Source | 28,953,000Source | 30,047,000Source | 37,360,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 15,000Source | 24,000Source | 6,000Source | 17,000Source | 9,000Source | 19,000Source | 63,000Source | 102,000Source | — | — |
| Investment Income, InterestUSD | — | — | 3,169,000Source | 2,107,000Source | 2,325,000Source | 1,859,000Source | 2,586,000Source | 1,326,000Source | 9,224,000Source | 6,940,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -32,733,000Source | -25,524,000Source | -46,639,000Source | -26,882,000Source | -42,410,000Source | -21,529,000Source | -108,995,000Source | -89,298,000Source | -111,566,000Source | -166,014,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -32,733,000Source | -25,524,000Source | -46,639,000Source | -26,882,000Source | -42,410,000Source | -21,529,000Source | -108,995,000Source | -89,298,000Source | -111,566,000Source | -166,014,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,291,000Source | 374,000Source | 710,000Source | -129,000Source | 1,076,000Source | -108,000Source | 1,503,000Source | 2,161,000Source | -39,127,000Source | -3,567,000Source |
| Operating ExpensesUSD | — | — | 34,024,000Source | 27,686,000Source | 47,349,000Source | 28,739,000Source | 43,486,000Source | 23,723,000Source | 120,271,000Source | 99,792,000Source | 87,890,000Source | 164,949,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -37,000Source | -81,000Source | -88,000Source | -237,000Source | -31,000Source | 13,000Source | -291,000Source | -110,000Source | -47,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 516,000Source | — | 1,220,000Source | — | — | — |
| Gain (Loss) on Disposition of Assets | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Gain (Loss) on Termination of Lease | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 1,788,000Source | 0Source | 1,986,000Source | 0Source | 2,302,000Source | 9,773,000Source | 8,333,000Source | 15,451,000Source | 2,502,000Source |
| Operating Income (Loss)USD | — | — | -34,024,000Source | -25,898,000Source | -47,349,000Source | -26,753,000Source | -43,486,000Source | -21,421,000Source | -110,498,000Source | -91,459,000Source | -72,439,000Source | -162,447,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -37,000Source | -81,000Source | -88,000Source | -237,000Source | -31,000Source | 13,000Source | -291,000Source | -110,000Source | -47,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -32,733,000Source | -25,524,000Source | -46,639,000Source | -26,882,000Source | -42,410,000Source | -21,529,000Source | -108,995,000Source | -89,298,000Source | -111,566,000Source | -166,014,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.09Source | -0.1Source | -0.13Source | -0.09Source | -0.12Source | -0.08Source | -0.34Source | -0.36Source | -0.96Source | -3.78Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.09Source | -0.1Source | -0.13Source | -0.09Source | -0.12Source | -0.08Source | -0.34Source | -0.36Source | -0.96Source | -3.78Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 353,309,524Source | 267,824,045Source | 369,044,040Source | 297,988,978Source | 366,632,827Source | 269,306,331Source | 319,711,972Source | 250,134,421Source | 116,121,482Source | 43,952,015Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 353,309,524Source | 267,824,045Source | 369,044,040Source | 297,988,978Source | 366,632,827Source | 269,306,331Source | 319,711,972Source | 250,134,421Source | 116,121,482Source | 43,952,015Source |
| Interest Expense (non-operating)USD | — | — | 15,000Source | 24,000Source | 6,000Source | 17,000Source | 9,000Source | 19,000Source | 63,000Source | 102,000Source | — | — |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 8,279,000Source | 7,902,000Source | 12,146,000Source | 8,598,000Source | 9,677,000Source | 8,158,000Source | 33,868,000Source | 28,953,000Source | 30,047,000Source | 37,360,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 4,998,000Source | 3,798,000Source |
| Interest Income (Expense), Nonoperating, NetUSD | — | — | — | — | — | — | — | — | — | — | 3,572,000Source | 249,000Source |
| Investment Income, InterestUSD | — | — | 3,169,000Source | 2,107,000Source | 2,325,000Source | 1,859,000Source | 2,586,000Source | 1,326,000Source | 9,224,000Source | 6,940,000Source | — | — |
| Labor and Related ExpenseUSD | — | — | 11,111,000Source | 9,283,000Source | 16,377,000Source | 10,850,000Source | 15,390,000Source | 11,270,000Source | 47,680,000Source | 36,372,000Source | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -32,733,000Source | -25,524,000Source | -46,639,000Source | -26,882,000Source | -42,410,000Source | -21,529,000Source | -108,995,000Source | -89,298,000Source | -111,566,000Source | -166,014,000Source |
| Nonoperating Income (Expense)USD | — | — | 1,291,000Source | 374,000Source | 710,000Source | -129,000Source | 1,076,000Source | -108,000Source | 1,503,000Source | 2,161,000Source | -39,127,000Source | -3,567,000Source |
| Operating ExpensesUSD | — | — | 34,024,000Source | 27,686,000Source | 47,349,000Source | 28,739,000Source | 43,486,000Source | 23,723,000Source | 120,271,000Source | 99,792,000Source | 87,890,000Source | 164,949,000Source |
| Research and Development ExpenseUSD | — | — | 25,745,000Source | 14,946,000Source | 38,636,000Source | 20,141,000Source | 33,809,000Source | 15,565,000Source | 86,403,000Source | 66,001,000Source | 56,778,000Source | 91,169,000Source |
Filing attachments
d161230dex991.htm · 8-K · 2026-08-11
EX-99.1 2 d161230dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027 TSHA-102 continues to be generally well tolerated with no severe treatment-related SAEs or DLTs across REVEAL …
Read attachment ↗d121397dex41.htm · 8-K · 2026-06-25
EX-4.1 3 d121397dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK TAYSHA GENE THERAPIES, INC. Warrant Shares: [•] Issue Date: [•], 2026 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [•] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until …
Read attachment ↗d121397dex991.htm · 8-K · 2026-06-25
EX-99.1 5 d121397dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants DALLAS, June 24, 2026 - Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering …
Read attachment ↗d121397dex992.htm · 8-K · 2026-06-25
EX-99.2 6 d121397dex992.htm EX-99.2 EX-99.2 Exhibit 99.2 Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants DALLAS, June 24, 2026 - Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32…
Read attachment ↗d20817dex991.htm · 8-K · 2026-06-22
EX-99.1 2 d20817dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer- Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome Completed dosing of 17 patients in REVEAL pivotal trial; topline data from 6-month interim analysis and FDA feedback on next steps toward BLA submission pathway expected 1H 2027 TSHA-102 was generally well-tolerated with no treatment-related…
Read attachment ↗d20817dex992.htm · 8-K · 2026-06-22
EX-99.2 3 d20817dex992.htm EX-99.2 EX-99.2 TSHA-102 Rett Syndrome program Update: Longer-term Results from REVEAL Phase 1/2 trials June 2026 Exhibit 99.2 This presentation is intended to be viewed by investors in the U.S. only Legal disclosure FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regardi…
Read attachment ↗